OncoMatch/Clinical Trials/NCT06465563

Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer

Is NCT06465563 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including SHR-8068 and Adebrelimab for biliary tract cancer.

Phase 2RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06465563Data as of May 2026

Treatment: SHR-8068 · Adebrelimab · Cisplatin · Gemcitabine — This study aims to evaluate the efficacy and safety of SHR-8068 and Adebrelimab in Combination With Cisplatin Plus Gemcitabine(CisGem), compared with Adebrelimab in Combination With CisGem, as first-line treatment in patients with Advanced Biliary Tract cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cholangiocarcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

Kidney function

Liver function

Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify